Company
Phathom Pharmaceuticals, Inc.
Headquarters: Florham Park, NJ, United States
Employees: 77
CEO: Ms. Terrie J. Curran
Market Cap
$622.7 Million
USD as of July 1, 2025
Phathom Pharmaceuticals, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $682,000 |
| EBITDA | $-166,736,992 |
| Gross Profit TTM | $515,000 |
| Profit Margin | 75.51% |
| Operating Margin | -10245.60% |
| Quarterly Revenue Growth | % |
Stocks & Indices
Phathom Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: PHAT wb_incandescent